세계의 ELAHERE 시장 : 기회와 전략(-2034년)

Elahere Global Market Opportunities And Strategies To 2034

US $ 4,490 ￦ 6,147,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,885,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,623,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

ELAHERE(밀베툭시맙 소라부탄신 징크스)는 엽산 수용체 α(FRa) 양성 난소암, 난관암, 원발성 복막암 성인 환자의 치료를 목적으로 한 처방약입니다.

ELAHERE 시장은 엽산 수용체 α(FRa)를 고발현하는 백금 제제 저항성의 상피성 난소암, 난관암, 원발성 복막암을 치료하기 위해 특별히 설계된 표적 항체 약물 복합체(ADC)인 ELAHERE(mirvetuximab soravtansine-gynx)의 사업체(조직, 개인사업자, 파트너십)에 의한 판매로 구성되어 있습니다.

세계의 ELAHERE 시장 규모는 2024년 5억 256만 달러에 달했습니다. 실적 기간의 성장은 기술의 진보와 맞춤형 의료에 대한 수요 증가에 기인하고 있습니다.

건강 관리 지출 증가

헬스케어 지출 증가는 이 실적 기간에 ELAHERE 시장의 확대를 뒷받침했습니다. 헬스케어 지출이란 의료비에 대한 지출을 가리키고, 특정 의료제도나 경제권 내에서 헬스케어 관련 상품이나 서비스에 소비되는 총액입니다. 헬스케어 분야의 재원이 증가함에 따라 혁신적인 치료 및 연구개발에 대한 투자가 확대됩니다. 이 자금은 임상시험, 규제 당국의 승인, ELAHERE와 같은 최첨단 치료제의 생산 규모 확대와 관련된 높은 비용을 다루는 데 도움이 됩니다. 예를 들어 미국에 본사를 둔 비영리 단체인 Canadian Institute for Health Information에 따르면 2023년 캐나다의 총 의료비는 3,440억 달러(1인당 8,740달러)에 이를 것으로 추정됐습니다.

Abbvie, 백금 제형 저항성 난소암에서 엘라 헤어의 유럽 승인 획득

ELAHERE 시장의 각 회사는 백금 제형 저항성 난소암 환자에 대한 치료 가능성을 확대하기 위해 규제 당국의 승인 취득에 주력하고 있습니다. 이러한 움직임은 고급 치료 옵션을 필요로 하는 특정 환자 그룹에 표적 치료를 제공함으로써 시장에서의 입지를 강화하는 것을 목표로 합니다. 예를 들어 미국의 생명공학 기업인 Abbbvie는 2024년 11월 엽산 수용체 α(FRα) 양성 백금 제제 저항성 난소암 성인 환자에 대한 치료제로 유럽 위원회로부터 엘라헤어 승인을 취득했습니다. 이번 승인은 3상 임상시험인 MIRASOL 시험의 양호한 결과를 바탕으로 하였으며, 표준 화학요법에 비해 병세 진행 또는 사망 위험이 35% 감소하는 것으로 나타났습니다.

세계의 ELAHERE 시장은 매우 집중되어 있으며, 참가 기업은 1사 뿐입니다.

The Business Research Company의 'ELAHERE Global Market Opportunities And Strategies To 2034'는 전략 담당자, 마케팅 담당자, 고위 경영진을 대상으로 COVID-19 봉쇄에서 일어나는 세계 ELAHERE 시장을 평가하는 데 필요한 중요한 정보를 제공합니다.

구매 이유

• 10 지역을 커버하는 이 시장에 관한 가장 종합적인 보고서에 의해 진정으로 세계적인 시점을 얻을 수 있습니다.
• 시장이 코로나바이러스로부터 어떤 영향을 받고 있는지, 또한 바이러스의 영향이 완화됨에 따라 시장이 어떻게 부상하고 성장해 나가는지를 이해합니다.
• 현지의 데이터와 분석에 근거해, 지역별 및 국가별 전략을 책정
• 투자의 대상이 되는 성장 부문을 특정
• 예측 데이터와 시장을 형성하는 촉진요인과 동향을 활용하여 경쟁사를 능가
• 최신 시장 조사 결과에 근거해 고객을 이해
• 주요 경쟁사와의 성능 비교
• 주요 데이터 세트 간의 관계를 활용하여 뛰어난 전략을 세울 수 있습니다.
• 신뢰성이 높은 고품질의 데이터와 분석을 통해 사내외 프레젠테이션을 지원하기에 적합

ELAHERE의 최대 시장, 급성장 시장은 어디인가? 경제 전체, 인구 동태, 다른 유사 시장과의 관계는? 향후 시장을 형성하는 세력은 무엇인가?

이 보고서는 시장 특징, 규모와 성장, 세분화, 지역별 및 국가별 분석, 경쟁 구도, 시장 점유율, 시장 동향과 전략에 대해 설명하고 있습니다.

이 보고서는 다음 장을 다룹니다.

• 소개 및 시장 특성 - 임상 적응증별, 유통 채널별, 최종 사용자별 등 시장 세분화를 간단하게 소개하고 정의와 해설을 더하고 있습니다.
• 세계의 주요 동향 - 세계 시장을 형성하는 주요 동향을 하이라이트.또, 향후 시장 개척에 대해서도 다룹니다.
• 성장 분석과 전략적 분석 프레임워크 PESTEL, 최종용도산업, 시장성장률, 세계실적(2019-2024년) 및 예측(2024-2029년, 2034년)
• 지역별 및 국가별 분석 - 지역별 및 국가별 과거(2019년-2024년)와 예측(2024년-2029년, 2034년) 시장 가치와 성장률, 시장 점유율 비교
• 시장 세분화 - 시장의 임상 적응증별, 유통 채널별, 최종 사용자별 시장 가치(2024년-2029년, 2034년)와 각 부문별 분석을 수록. 지역 시장별 과거(2019년-2024년), 예측(2024년-2029년, 2029년-2034년) 시장 가치와 성장률, 시장 점유율 비교를 게재.
• 지역별 시장 규모와 성장률 - 지역별 시장 규모(2024년), 지역내 각국의 과거(2019년-2024년) 및 예측(2024년-2029년, 2034년) 시장가치와 성장률, 시장 점유율 비교.
• 경쟁 구도 - 시장 경쟁 구도의 상세, 추정 시장 점유율, 주요 기업의 기업 프로파일을 제공합니다.
• 주요 M&A - 시장의 최근 M&A에 관한 정보를 제공합니다.
• 시장 세분화 - 조사 결과에 근거한 시장 기회와 전략에 대해서, 나라나 부문 마다의 성장 기회나, 그러한 시장에서 취해야 할 전략에 관한 정보를 기재하고 있습니다.
• 결론 및 제안 - 이 섹션에서는 제품 및 서비스 제공 지역 확대, 마케팅 전략, 타겟 그룹 등 ELAHERE 프로바이더에 대한 제안을 제공합니다.
• 부록: 본 보고서에서 사용되고 있는 NAICS 코드, 약어, 통화 코드의 상세가 기재되어 있습니다.

본 보고서는 세계의 ELAHERE 시장에 대해 조사했으며, 시장 개요와 함께 임상 적응증별, 유통 채널별, 최종 사용자별, 지역 및 국가별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 주요 요약

• ELAHERE - 시장의 매력과 거시경제 상황

제2장 목차

제3장 테이블 목록

제4장 도표 일람

제5장 보고서 구성

제6장 시장 특징

• 일반 시장 정의
• 요약
• ELAHERE 시장 정의와 세분화
• 임상 적응증별 시장 세분화
  • 난소 종양
  • 난관 종양
  • 복막 종양
• 유통 채널별 시장 세분화
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 최종 사용자별 시장 세분화
  • 병원
  • 전문센터
  • 기타

제7장 ELAHERE 시장의 생물학적 의약품의 특징

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제8장 주요 시장 동향

• Abbvie가 백금 제제 내성 난소암 치료제 「ELAHERE」의 유럽 승인을 취득
• 진행난소암 치료에 있어서의 전략적 제휴 목표
• 첨단 진단 도구가 난소암 치료의 향상을 목표로

제9장 세계 ELAHERE 성장 분석과 전략 분석 프레임워크

• 세계 ELAHERE PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인)

제10장 B2B 시장의 최종 사용자 분석

• 최종 사용자
• 세계 시장 규모와 성장
• 시장 규모
• 시장 성장 실적, 2019년-2024년
• 시장 성장 예측, 2024년-2029년, 2034년
• 세계의 ELAHERE 총 시장 규모(TAM)

제11장 세계의 ELAHERE의 가격 분석과 예측

제12장 세계의 ELAHERE 시장 세분화

• 세계의 ELAHERE 시장, 임상적응증별
• 세계의 ELAHERE 시장, 유통 채널별
• 세계의 ELAHERE 시장, 최종 사용자별

제13장 임상적응증의 세계 역학

• 임상적응증의 발생률과 유병률

제14장 ELAHERE 시장, 지역별·국가별 분석

• 세계의 ELAHERE 시장, 지역별, 분석 및 예측, 2019년-2024년, 2029년, 2034년
• 세계의 ELAHERE 시장, 국가별, 분석 및 예측, 2019년-2024년, 2029년, 2034년

제15장 아시아태평양 시장

제16장 서유럽 시장

제17장 동유럽 시장

제18장 북미 시장

제19장 남미 시장

제20장 중동 시장

제21장 아프리카 시장

제22장 경쟁 구도와 기업 프로파일

• 기업 프로파일
• AbbVie Inc.(ImmunoGen)

제23장 세계 ELAHERE 시장의 파이프라인 분석

제24장 주요 인수합병(M&A)

• AbbVie가 ImmunoGen 인수

제25장 기회와 전략

• 2029년 세계의 ELAHERE 시장 - 가장 새로운 기회를 제공하는 국가
• 2029년 세계의 ELAHERE 시장 - 가장 새로운 기회를 제공하는 부문
• 2029년 세계의 ELAHERE 시장 - 성장 전략

제26장 ELAHERE 시장, 결론 및 제안

제27장 부록

JHS

영문 목차

영문목차

Elahere (mirvetuximab soravtansine-gynx) is a prescription medication designed for the treatment of adult patients with folate receptor-alpha (FRa) positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is specifically indicated for individuals who have not responded to or are no longer responding to platinum-based chemotherapy and have received one to three prior types of chemotherapy. Elahere functions as an antibody-drug conjugate (ADC), delivering a cytotoxic agent directly to FRa-positive cancer cells, thereby minimizing damage to healthy tissues.

The elahere market consists of sales, by entities (organizations, sole traders or partnerships), of elahere (mirvetuximab soravtansine-gynx), a targeted antibody-drug conjugate (ADC) specifically designed for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRa).

The global elahere market accounted to $502.56 million in 2024. The growth in the historic period can be attributed to technological advancements and increase in demand for personalized medicine.

Rising Healthcare Expenditure

The rising healthcare expenditure supported the expansion of the elahere market during this historic period. Healthcare expenditure refers to spending on healthcare costs and represents the total amount of money spent on healthcare-related goods and services within a given healthcare system or economy. Increased financial resources in the healthcare sector enable greater investment in innovative treatments, research and development. This funding helps cover the high costs associated with clinical trials, regulatory approvals and the scaling of production for cutting-edge therapies like Elahere. For instance, in 2023, according to the Canadian Institute for Health Information, a US-based not-for-profit organization, Canada's total health spending was estimated to reach $344 billion, or $8,740 per person. The growth in physician spending was estimated to be 6.9% in 2023 and 9.5% in 2022. Therefore, rising healthcare expenditure drove the growth of the elahere market.

Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer

Companies in the elahere market are focusing on obtaining regulatory approvals to expand the treatment's availability for patients with platinum-resistant ovarian cancer. This move aims to strengthen its position in the market by offering a targeted therapy for a specific patient group in need of advanced treatment options. For instance, in November 2024, AbbVie, a US-based biotech company received approval from the European Commission for elahere as a treatment for adult patients with folate receptor-alpha (FR alpha) positive, platinum-resistant ovarian cancer. The approval was based on the positive results from the Phase III MIRASOL trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.

The global elahere market is highly concentrated, with only one player in the market. The top competitor in the market made up 100.0% of the total market in 2023.

Elahere Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global elahere market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for elahere? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The elahere market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider elahere market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by distribution channel and by end-users.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by distribution channel and by end-users in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for elahere providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Clinical Indication: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End-User: Hospitals; Specialty Centers; Other End-Users
• Companies Mentioned: AbbVie Inc. (ImmunoGen)
• Countries: China; Australia; India; Japan; South Korea; USA; Canada; France; Germany; UK
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; elahere indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Elahere - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Elahere Market Definition And Segmentations
• 6.4 Market Segmentation By Clinical Indication
  • 6.4.1 Ovarian Neoplasms
  • 6.4.2 Fallopian Tube Neoplasms
  • 6.4.3 Peritoneal Neoplasms
• 6.5 Market Segmentation By Distribution Channel
  • 6.5.1 Hospital Pharmacies
  • 6.5.2 Retail Pharmacies
  • 6.5.3 Online Pharmacies
• 6.6 Market Segmentation By End-Users
  • 6.6.1 Hospitals
  • 6.6.2 Specialty Centers
  • 6.6.3 Other End-Users

7 Elahere Market Biologic Drug Characteristics

• 7.1 Molecule Type
• 7.2 Route Of Administration (ROA)
• 7.3 Mechanism Of Action (MOA)
• 7.4 Safety And Efficacy

8 Major Market Trends

• 8.1 Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer
• 8.2 Strategic Collaboration Targets For Advanced Ovarian Cancer Treatment
• 8.3 Advanced Diagnostic Tool Aims to Enhance Ovarian Cancer Treatment

9 Global Elahere Growth Analysis And Strategic Analysis Framework

• 9.1 Global Elahere PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
  • 9.1.1 Political
  • 9.1.2 Economic
  • 9.1.3 Social
  • 9.1.4 Technological
  • 9.1.5 Environmental
  • 9.1.6 Legal

10 Analysis Of End Users For B2B Markets

• 10.1 End Users
  • 10.1.1 Hospitals
  • 10.1.2 Specialty Centers
  • 10.1.3 Other End Users
• 10.2 Global Market Size and Growth
• 10.3 Market Size
• 10.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 10.4.1 Market Drivers 2019 - 2024
  • 10.4.2 Market Restraints 2019 - 2024
• 10.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 10.5.1 Market Drivers 2024 - 2029
  • 10.5.2 Market Restraints 2024 - 2029
• 10.6 Global Elahere Total Addressable Market (TAM)

11 Global Elahere Pricing Analysis & Forecasts

12 Global Elahere Market Segmentation

• 12.1 Global Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.2 Global Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.3 Global Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Global Elahere Epidemiology Of Clinical Indications

• 13.1 Incidence And Prevalence of Clinical Indications

14 Elahere Market, Regional and Country Analysis

• 14.1 Global Elahere Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.2 Global Elahere Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 Asia-Pacific Market

• 15.1 Market Overview
  • 15.1.1 Region Information
  • 15.1.2 Background Information
  • 15.1.3 Government Initiatives
  • 15.1.4 Regulations
  • 15.1.5 Regulatory Bodies
  • 15.1.6 Major Associations
  • 15.1.7 Taxes Levied
  • 15.1.8 Corporate Tax Structure
  • 15.1.9 Investments
• 15.2 Asia-Pacific Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.3 Asia-Pacific Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 Asia-Pacific Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 Asia-Pacific Elahere Market: Country Analysis
• 15.6 China Market
• 15.7 Market Overview
  • 15.7.1 Country Information
  • 15.7.2 Background Information
  • 15.7.3 Government Initiatives
  • 15.7.4 Regulations
  • 15.7.5 Regulatory Bodies
  • 15.7.6 Major Associations
  • 15.7.7 Taxes Levied
  • 15.7.8 Corporate Tax Structure
  • 15.7.9 Investments
• 15.8 China Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 China Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.10 China Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.11 India Market
• 15.12 India Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.13 India Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.14 India Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.15 Japan Market
• 15.16 Market Overview
  • 15.16.1 Country Information
  • 15.16.2 Background Information
  • 15.16.3 Regulations
  • 15.16.4 Regulatory Bodies
  • 15.16.5 Major Associations
  • 15.16.6 Taxes Levied
  • 15.16.7 Corporate Tax Structure
  • 15.16.8 Investments
• 15.17 Japan Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.18 Japan Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.19 Japan Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.20 Australia Market
• 15.21 Australia Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.22 Australia Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.23 Australia Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.24 South Korea Market
• 15.25 Market Overview
  • 15.25.1 Country Information
  • 15.25.2 Background Information
  • 15.25.3 Government Initiatives
  • 15.25.4 Regulations
  • 15.25.5 Regulatory Bodies
  • 15.25.6 Major Associations
  • 15.25.7 Taxes Levied
  • 15.25.8 Corporate Tax Structure
• 15.26 South Korea Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.27 South Korea Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.28 South Korea Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Western Europe Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate tax structure
  • 16.2.10 Investments
• 16.3 Western Europe Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Western Europe Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Western Europe Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.6 Western Europe Elahere Market: Country Analysis
• 16.7 UK Market
• 16.8 UK Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.9 UK Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.10 UK Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.11 Germany Market
• 16.12 Germany Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.13 Germany Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.14 Germany Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.15 France Market
• 16.16 France Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.17 France Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.18 France Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Eastern Europe Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Association
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
• 17.3 Eastern Europe Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Eastern Europe Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Eastern Europe Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 North America Market

• 18.1 Summary
• 18.2 Market Overview
  • 18.2.1 Region Information
  • 18.2.2 Market Information
  • 18.2.3 Background Information
  • 18.2.4 Government Initiatives
  • 18.2.5 Regulations
  • 18.2.6 Regulatory Bodies
  • 18.2.7 Major Associations
  • 18.2.8 Taxes Levied
  • 18.2.9 Corporate Tax Structure
  • 18.2.10 Investments
• 18.3 North America Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.4 North America Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.5 North America Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.6 North America Elahere Market: Country Analysis
• 18.7 USA Market
• 18.8 Summary
• 18.9 Market Overview
  • 18.9.1 Country Information
  • 18.9.2 Market Information
  • 18.9.3 Background Information
  • 18.9.4 Government Initiatives
  • 18.9.5 Regulations
  • 18.9.6 Regulatory Bodies
  • 18.9.7 Major Associations
  • 18.9.8 Taxes Levied
  • 18.9.9 Corporate Tax Structure
  • 18.9.10 Investments
• 18.1 USA Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.11 USA Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.12 USA Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.13 Canada Market
• 18.14 Market Overview
  • 18.14.1 Country Information
  • 18.14.2 Background Information
  • 18.14.3 Government Initiatives
  • 18.14.4 Regulations
  • 18.14.5 Regulatory Bodies
  • 18.14.6 Major Associations
  • 18.14.7 Taxes Levied
  • 18.14.8 Corporate Tax Structure
• 18.15 Canada Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.16 Canada Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.17 Canada Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 South America Market

• 19.1 Market Overview
  • 19.1.1 Region Information
  • 19.1.2 Background Information
  • 19.1.3 Government Initiatives
  • 19.1.4 Regulations
  • 19.1.5 Regulatory Bodies
  • 19.1.6 Major Associations
  • 19.1.7 Taxes Levied
  • 19.1.8 Corporate Tax Structure
• 19.2 South America Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 19.3 South America Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 19.4 South America Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

20 Middle East Market

• 20.1 Market Overview
  • 20.1.1 Region Information
  • 20.1.2 Market Information
  • 20.1.3 Background Information
  • 20.1.4 Government Initiatives
  • 20.1.5 Regulations
  • 20.1.6 Regulatory Bodies
  • 20.1.7 Major Associations
  • 20.1.8 Taxes Levied
  • 20.1.9 Corporate Tax Structure
• 20.2 Middle East Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 20.3 Middle East Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 20.4 Middle East Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

21 Africa Market

• 21.1 Market Overview
  • 21.1.1 Region Information
  • 21.1.2 Background Information
  • 21.1.3 Government Initiatives
  • 21.1.4 Regulations
  • 21.1.5 Regulatory Bodies
  • 21.1.6 Major Associations
  • 21.1.7 Taxes Levied
  • 21.1.8 Corporate Tax Structure
• 21.2 Africa Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 21.3 Africa Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 21.4 Africa Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

22 Competitive Landscape And Company Profiles

• 22.1 Company Profiles
• 22.2 AbbVie Inc. (ImmunoGen)
  • 22.2.1 Company Overview
  • 22.2.2 Products And Services
  • 22.2.3 Business Strategy
  • 22.2.4 Financial Overview

23 Global Elahere Market Pipeline Analysis

24 Key Mergers And Acquisitions

• 24.1 AbbVie Acquired ImmunoGen

25 Opportunities And Strategies

• 25.1 Global Elahere Market In 2029 - Countries Offering Most New Opportunities
• 25.2 Global Elahere Market In 2029 - Segments Offering Most New Opportunities
• 25.3 Global Elahere Market In 2029 - Growth Strategies
  • 25.3.1 Market Trend Based Strategies
  • 25.3.2 Competitor Strategies

26 Elahere Market, Conclusions And Recommendations

• 26.1 Conclusions
• 26.2 Recommendations
  • 26.2.1 Product
  • 26.2.2 Place
  • 26.2.3 Price
  • 26.2.4 Promotion
  • 26.2.5 People

27 Appendix

• 27.1 Geographies Covered
• 27.2 Market Data Sources
• 27.3 Research Methodology
• 27.4 Currencies
• 27.5 The Business Research Company
• 27.6 Copyright and Disclaimer

관련자료